blue digital circular waveforms

Press Releases

June 4, 2024

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference

NASHUA, N.H. – June 4, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June…

May 15, 2024

iCAD Reports Financial Results for First Quarter Ended March 31, 2024

NASHUA, N.H. – May 15, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter…

May 2, 2024

iCAD to Report First Quarter 2024 Financial Results on May 15, 2024

UPDATE: Call Time is 8:30 AM Eastern Time NASHUA, N.H., May 2, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at…

April 11, 2024

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

NASHUA, N.H., April 11, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will showcase its ProFound Breast Health Suite of AI solutions, including the newly released ProFound Cloud, powered by Google Cloud and Google Health AI architecture, while also…

April 9, 2024

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

NASHUA, NH, and HALIFAX, NS, April 9, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc., a global leader in operational AI solutions for breast cancer screening. The partnership enables breast imaging centers and radiologists to…

April 8, 2024

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Study confirms iCAD’s Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms NASHUA, N.H. – April 8, 2024 – iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its AI-powered…

April 3, 2024

iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

iCAD implements ProFound AI Detection to improve mammography reading and breast cancer detection in low-resource institutions and medically underserved communities. NASHUA, N.H., April 3, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with…

April 2, 2024

iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

ProFound Cloud redefines accessibility to critical insights, empowering radiologists in early breast cancer detection NASHUA, N.H. – April 2, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud. The innovative Software-as-a-Service (SaaS) platform provides medical providers…

March 19, 2024

iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

Newly released capabilities — limiting the number of marks on a 3D view, color-coding lesion marks, and color-coding the ProFound Scorecard — enhance radiologists’ interpretability and efficiency NASHUA, N.H. – March 19, 2024 – iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers…

March 12, 2024

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M NASHUA, N.H. – March 12, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical…